OR WAIT null SECS
November 02, 2008
IPEC Chairman Dave Schoneker discusses current efforts toward facilitating regulatory reviews of new excipients.
October 01, 2008
The potent nature of HPAPIs means there must be careful evaluation of the compound for its level of toxicity when considering manufacture.
September 01, 2008
Near-infrared spectroscopy (NIR) is suitable for the analysis of pharmaceutical samples in various solid forms, and can be used for determining chemical properties (e.g., content of drug, water), as well as physical properties (e.g., particle size, tablet hardness).
July 02, 2008
Clear labels for substances that can be used as excipients, APIs, or both are critical to end-product use.
May 02, 2008
The less complex nature of excipient manufacturers, as compared with API manufactures, carries many benefits.
May 01, 2008
The pharmaceutical industry must address the release of nonbiodegradable APIs into the environment.
April 02, 2008
A changing regulatory environment is on the horizon for excipient suppliers and users.
December 01, 2007
Lipid-based drug delivery systems - such as liposomes, micro-and nanoemulsions, self-emulsified drug delivery systems, and solid lipid micro-and nanoparticles - are becoming more popular because lipid materials are easily characterized, contain a high range of well-defined/tolerated surfactant molecules and can be developed for several administration routes.
November 01, 2007
The crystalline structure of pharmaceutical solids can sometimes be altered during processing. X-ray powder diffraction and near infrared spectroscopy can be used to determine the amorphous and crystalline content of a model substance. The two techniques' precision, accuracy, detection limit and the speed of analysis are compared.